Investor Relations

Corporate Profile

Nurix Therapeutics discovers drugs that harness the body’s natural process to control protein levels. Our drugs control ubiquitin E3 ligases, the key enzymes responsible for protein breakdown in human cells, as a unique therapeutic approach called targeted protein modulation to treat a broad range of diseases. Our focus is on developing targeted therapies to treat cancer including novel, small molecule immuno-oncology agents.

Data Provided by Refinitiv. Minimum 15 minutes delayed.


May 6, 2021
Annual Meeting of Stockholders
April 14, 2021 at 11:45 AM EDT
20th Annual Needham Virtual Healthcare Conference
March 17, 2021 at 3:10 PM EDT
Oppenheimer 31st Annual Healthcare Conference (Virtual)